RE:RE:RE:RE:RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer ImmunotherapyFor those intent on casting shawdows on company accomplishements, I have already referenced that in the chalenge of overcoming the hypoxia that characterizes solid tumors and a hostile TME, ONCY's oncolytic virus pelareorep (reovirus) is able to down-regulate HIF-1α signaling, resulting in HIF-1α inhibition, and by doing so is able to convert an otherwise aggressive and hypoxic tumor microenvironment (TME) into one that can promote T cell function, and is conducive for immune checkpoint inhibition, as the AWARE-1 study is demonstrating.
I suggest those involved in manipulation of the stock think about what AOI is about to present at SABC in December and how Big Pharma is about to respond to these results going forward.